- Conditions
- Neonatal Sepsis
- Interventions
- Ceftobiprole medocaril
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 3 Days to 3 Months
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Evanston, Illinois • Morgantown, West Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
- Interventions
- Hematopoietic stem cell transplant (HSCT)
- Biological
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- RSV Infection, Bronchiolitis
- Interventions
- Collection of exhaled breath
- Other
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 1 Day to 4 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Pseudomonas Infection
- Interventions
- Ciprofloxacin (Cipro, BAYQ3939)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Cystic Fibrosis
- Interventions
- Supportive Care Intervention
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Growth and Tolerance Infant Study
- Interventions
- Experimental Infant Formula
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- Up to 9 Months
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Premature Birth, Premature Infant, Premature, Intrauterine Growth Restriction, Small for Gestational Age at Delivery
- Interventions
- PEAPOD Infant Body Composition measuring device
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 22 Weeks to 32 Weeks
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273.214, Placebo
- Biological · Other
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 2 Months to 6 Months
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 39
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
- Conditions
- Healthy Growth
- Interventions
- New Organic Infant Formula, Commercial Organic Infant Formula
- Other
- Lead sponsor
- Bobbie Baby, Inc
- Industry
- Eligibility
- 0 Days to 11 Days
- Enrollment
- 394 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Indian Harbour Beach, Florida
- Conditions
- Heart Defects, Congenital
- Interventions
- Clopidogrel (SR25990), placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Up to 92 Days
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Lice Infestations
- Interventions
- MALG
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • St. Petersburg, Florida • West Palm Beach, Florida + 2 more
- Conditions
- Cholestasis, Cholestasis of Parenteral Nutrition
- Interventions
- Omegaven
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 14 Days to 5 Years
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Traumatic Lumbar Puncture
- Interventions
- Spinal Sonography
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Miami, Florida • Memphis, Tennessee + 1 more
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- UNEX-42, Phosphate-buffered saline
- Biological
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 3 Days to 14 Days
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 1 more
- Conditions
- Cystic Fibrosis
- Interventions
- Lefamulin
- Drug
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Kansas City, Kansas • Boston, Massachusetts • Valhalla, New York + 3 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Aplastic Anemia, Burkitt Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Paroxysmal Nocturnal Hemoglobinuria, Peripheral T-cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Severe Combined Immunodeficiency, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
- Interventions
- fludarabine phosphate, melphalan, total-body irradiation, tacrolimus, mycophenolate mofetil, methotrexate, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Radiation · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 3 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Twin to Twin Transfusion
- Interventions
- Fetoscopic Laser Photocoagulation
- Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brown Adipose Tissue, Body Composition
- Interventions
- Not listed
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 14 Days to 28 Days
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
- Interventions
- Cool-Cap
- Device
- Lead sponsor
- Olympic Medical
- Industry
- Eligibility
- 1 Hour to 6 Hours
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Oakland, California • San Diego, California + 15 more
- Conditions
- Fussy Infant (Baby)
- Interventions
- Infant Formula - Partially hydrolyzed protein, Infant Formula - Intact protein
- Other
- Lead sponsor
- Mead Johnson Nutrition
- Industry
- Eligibility
- 15 Days to 75 Days
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Miramar, Florida • Sarasota, Florida + 7 more
- Conditions
- Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
- Interventions
- AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more
- Conditions
- Congenital Heart Disease
- Interventions
- Parent Navigator Program, Standard of Care
- Behavioral
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Single Sided Deafness, Unilateral Deafness, Hearing Loss, Unilateral, Hearing Loss, Congenital Hearing Loss, Deafness One Ear
- Interventions
- Cochlear Implant
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 7 Months to 71 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina